These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15234797

  • 1. Evaluation of antitumor and toxic side effects of mitomycin C-estradiol conjugates.
    Ishiki N, Onishi H, Machida Y.
    Int J Pharm; 2004 Jul 26; 279(1-2):81-93. PubMed ID: 15234797
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice.
    Fujita T, Tamura T, Yamada H, Yamamoto A, Muranishi S.
    J Drug Target; 1997 Jul 26; 4(5):289-96. PubMed ID: 9169985
    [Abstract] [Full Text] [Related]

  • 3. In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180.
    Ishiki N, Onishi H, Machida Y.
    Biol Pharm Bull; 1998 Nov 26; 21(11):1180-6. PubMed ID: 9853409
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activities of conjugates of mitomycin C with estradiol benzoate and estradiol via glutaric acid in suspension dosage form.
    Ishiki N, Onishi H, Machida Y.
    Biol Pharm Bull; 2002 Oct 26; 25(10):1373-7. PubMed ID: 12392099
    [Abstract] [Full Text] [Related]

  • 5. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
    Sato M, Onishi H, Takahara J, Machida Y, Nagai T.
    Biol Pharm Bull; 1996 Sep 26; 19(9):1170-7. PubMed ID: 8889036
    [Abstract] [Full Text] [Related]

  • 6. [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma].
    Qu QL, Zhang YG, Yang LZ, Sun L.
    Zhonghua Zhong Liu Za Zhi; 2006 Apr 26; 28(4):257-60. PubMed ID: 16875622
    [Abstract] [Full Text] [Related]

  • 7. Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
    Kodama N, Murata Y, Asakawa A, Inui A, Hayashi M, Sakai N, Nanba H.
    Nutrition; 2005 May 26; 21(5):624-9. PubMed ID: 15850970
    [Abstract] [Full Text] [Related]

  • 8. [Effects of IgG-Fc-mitomycin C conjugate on cancer cells].
    Baba E.
    Hokkaido Igaku Zasshi; 1996 Mar 26; 71(2):271-81. PubMed ID: 8641681
    [Abstract] [Full Text] [Related]

  • 9. DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C.
    Saeki S, Nishiyama M, Toge T.
    Hiroshima J Med Sci; 1995 Sep 26; 44(3):55-63. PubMed ID: 8567314
    [Abstract] [Full Text] [Related]

  • 10. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
    Phillips RM, Burger AM, Loadman PM, Jarrett CM, Swaine DJ, Fiebig HH.
    Cancer Res; 2000 Nov 15; 60(22):6384-90. PubMed ID: 11103802
    [Abstract] [Full Text] [Related]

  • 11. Biological properties of conjugates of mitomycin C with estradiol benzoate and estradiol: their stability characteristics in biological media and their binding abilities to estrogen receptor.
    Ishiki N, Onishi H, Machida Y.
    Biol Pharm Bull; 1997 Oct 15; 20(10):1096-102. PubMed ID: 9353572
    [Abstract] [Full Text] [Related]

  • 12. [Synthesis and antitumor activities of conjugates of mitomycin C-polysaccharide from Tremella fuciformis].
    Ukai S, Kiriki H, Nagai K, Kiho T.
    Yakugaku Zasshi; 1992 Sep 15; 112(9):663-8. PubMed ID: 1469614
    [Abstract] [Full Text] [Related]

  • 13. [Antitumor effect of MMC mixed in Beriplast P].
    Yano K, Matsuoka H, Baba H, Konoe S, Seo Y, Saito T, Tomoda H.
    Gan To Kagaku Ryoho; 1995 Sep 15; 22(11):1629-31. PubMed ID: 7574778
    [Abstract] [Full Text] [Related]

  • 14. Tumour cell uptake of lactosaminated and intact N-succinyl-chitosans and antitumour effects of conjugates with mitomycin C.
    Kato Y, Onishi H, Machida Y.
    Anticancer Res; 2002 Sep 15; 22(5):2771-6. PubMed ID: 12529995
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacokinetic study of intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles].
    Liang H, Tang HW, Hao XS, Sun H, Li W.
    Zhonghua Zhong Liu Za Zhi; 2005 Jul 15; 27(7):412-5. PubMed ID: 16188126
    [Abstract] [Full Text] [Related]

  • 16. Contribution of chitosan and its derivatives to cancer chemotherapy.
    Kato Y, Onishi H, Machida Y.
    In Vivo; 2005 Jul 15; 19(1):301-10. PubMed ID: 15796190
    [Abstract] [Full Text] [Related]

  • 17. Preparation and antitumor activities of mitomycin C beta-(1-->6)-branched (1-->3)-beta-D-glucan conjugate.
    Usui S, Murashima K, Sakai M, Kiho T, Ukai S.
    Biol Pharm Bull; 1994 Sep 15; 17(9):1165-70. PubMed ID: 7841935
    [Abstract] [Full Text] [Related]

  • 18. A new cellular target for mitomycin C: a case for mitochondrial DNA.
    Pritsos CA, Briggs LA, Gustafson DL.
    Oncol Res; 1997 Sep 15; 9(6-7):333-7. PubMed ID: 9406239
    [Abstract] [Full Text] [Related]

  • 19. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor.
    Xi-Xiao Y, Jan-Hai C, Shi-Ting L, Dan G, Xv-Xin Z.
    Regul Toxicol Pharmacol; 2006 Dec 15; 46(3):211-7. PubMed ID: 17010489
    [Abstract] [Full Text] [Related]

  • 20. Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation.
    Seymour LW, Soyez H, De Marre A, Shoaibi MA, Schacht EH.
    Anticancer Drug Des; 1996 Jul 15; 11(5):351-65. PubMed ID: 8765529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.